CD40

Overview

CD40 is a cell-surface receptor in the tumor necrosis factor receptor superfamily that plays a central role in immune regulation. It is expressed on antigen-presenting cells (APCs) and is a key costimulatory molecule involved in activating adaptive immune responses. When engaged by agonists, CD40 can promote APC maturation and enhance downstream immune signaling, making it an important target in immunotherapy research.

Biologically, CD40 is relevant to both normal immune function and disease-associated inflammation. Because it can amplify immune activation, CD40 has been investigated in cancer, neuroinflammation, and other immune-linked conditions. In therapeutic contexts, CD40 agonism is being explored to strengthen antitumor immunity, although prior clinical experience has also highlighted safety concerns such as hepatotoxicity. Its role therefore sits at the intersection of immune stimulation, inflammatory signaling, and disease modulation.

Focus of Latest Publications

Recent studies have examined CD40 as both a therapeutic target and a disease-associated protein across cancer, neuroinflammation, and neurodevelopmental research.

In cancer immunotherapy, CD40 was used as the immune-activating component of a tumor-targeted bispecific antibody, KK2269. This agent was designed to bind epithelial cell adhesion molecule (EpCAM) on tumor cells and CD40 on APCs, with the goal of selectively activating APCs only in the presence of EpCAM-positive tumors. The study reported that docetaxel-induced immune activation showed antitumor synergy with this CD40 agonist strategy, supporting the idea that CD40-directed stimulation can be combined with chemotherapy to enhance antitumor responses.

A separate cancer study focused on pancreatic cancer and evaluated IL1R1 blockade in combination with CD40 agonist-mediated immunity. The authors noted that agonistic CD40 antibodies are promising but have shown only modest efficacy and significant hepatotoxicity in clinical trials. Their work investigated whether blocking IL1R1 could augment CD40-driven immune effects, indicating ongoing efforts to improve the therapeutic window and efficacy of CD40-based immunotherapy.

CD40 also appeared in proteome-wide Mendelian randomization work on B-cell malignancy. In that analysis, CD40 was identified as a protein-disease association in Hodgkin lymphoma, alongside other immune-related proteins such as TNFSF13 (APRIL) and TNFRS13B (TACI) in multiple myeloma and FAS in chronic lymphocytic leukemia. This supports a broader role for CD40 in B-cell–related malignancies and suggests it may be relevant as a biomarker or therapeutic target in lymphoma biology.

Outside oncology, CD40 was studied in neuroinflammation and brain injury models. In a chronic cerebral hypoperfusion model induced by bilateral common carotid artery stenosis, genistein-3'-sodium sulfonate improved neuroinflammation, blood-brain barrier function, and microglial activation by regulating TGR5. In that context, CD40 expression decreased together with IBA-1, iNOS, CD68, NF-κB p65, IL-1β, and caspase-3, while markers such as ZO-1, claudin-5, and CD206 increased. This pattern is consistent with reduced inflammatory microglial activation and improved neurovascular integrity.

CD40 was also included in a Mendelian randomization study examining inflammatory proteins and attention deficit hyperactivity disorder (ADHD). The study reported genetic evidence supporting a protective role of CD40 in ADHD and proposed a putative immunometabolic pathway linking CD40 to neurodevelopmental outcomes. This suggests that CD40 may have relevance beyond classical immune disease, potentially influencing brain-related phenotypes through inflammatory and metabolic mechanisms.

Key Publications

May Causal relationship between inflammatory proteins and attention deficit hyperactivity disorder: A serum-metabolites-mediated Mendelian randomization analysis. (Medicine, 2026, PMID 42216364): "This study provides genetic evidence supporting a protective role of CD40 in ADHD and highlights a putative immunometabolic pathway linking CD40 to neurodevelopmental outcomes."
May Genistein-3'-sodium sulfonate improves neuroinflammation, blood-brain barrier function, and microglial activation after chronic cerebral hypoperfusion by regulating TGR5. (Metabolic brain disease, 2026, PMID 42159788): "Along with these changes, TGR5, ZO-1, claudin-5, and CD206 increased, while the expression of IBA-1, iNOS, CD40, CD68, NF-κB p65, IL-1β, and caspase-3 decreased at protein and mRNA levels."
Apr Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269. (Cancer science, 2026, PMID 41989931): "We developed KK2269, a bispecific antibody targeting epithelial cell adhesion molecule (EpCAM) on tumor cells and CD40 on APCs, designed to selectively activate APCs in the presence of EpCAM-positive tumors."
Apr Proteome-wide Mendelian randomization identifies protein associations and therapeutic targets for B-cell malignancy. (Blood neoplasia, 2026, PMID 41859349): "We identified 27 protein-disease associations, including TNFSF13 (APRIL) and TNFRS13B (TACI) in multiple myeloma, CD40 in Hodgkin lymphoma, and FAS in chronic lymphocytic leukemia."
Apr IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer. (Scientific reports, 2026, PMID 41935073): "Agonistic CD40 antibodies are promising, but clinical trials have shown only modest efficacy and significant hepatotoxicity."